Alaunos net loss widens to $1 million in Q1 FY26

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.

TCRT

0.00
  • Alaunos Therapeutics posted a net loss of USD 1 million for the quarter ended March 31, 2026.
  • Research and development expense rose 23% to USD 427,000, driven by higher stock-based compensation, salary expense, consulting fees tied to obesity and metabolic disorder program.
  • General and administrative expense fell 22% to USD 585,000 on lower salary expense, insurance costs, filing fees, bank fees, travel costs following downsized operations.
  • Cash and cash equivalents totaled USD 350,000 at March 31, 2026, with monthly cash burn about USD 340,000; management expects funding into second quarter of 2026, raising substantial doubt about ability to continue as a going concern.
  • Preclinical obesity candidate ALN1003 advanced on non-GLP DIO mouse data showing dose-related body weight reductions and improvements in metabolic biomarkers; initial large-animal PK data supported further evaluation of twice-daily dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-227272), on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.